{"NzzI_iwAAAAJ": [["Zhihui Liu", 2020, "Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy."], ["Andrew Bayley", 2020, "Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy."], ["Peter WM Chung", 2020, "Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy."], ["Charles N Catton", 2020, "Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy."], ["Avinash Pilar", 2020, "Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy."], ["Vickie Kong", 2020, "Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy."], ["Tara Rosewall", 2020, "Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy."], ["Alejandro Berlin", 2020, "Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy."], ["Tim Craig", 2020, "Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy."], ["Danny Shehata", 2020, "Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy."], ["Padraig Richard Warde", 2020, "Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy."], ["Joelle Helou", 2020, "Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy."], ["Mary K Gospodarowicz", 2020, "Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy."], ["M L\u00f6schau", 2020, "Publications Repository-Helmholtz-Zentrum Dresden-Rossendorf"], ["E Schleicher", 2020, "Publications Repository-Helmholtz-Zentrum Dresden-Rossendorf"], ["M Schubert", 2020, "Publications Repository-Helmholtz-Zentrum Dresden-Rossendorf"], ["M Tschofen", 2020, "Publications Repository-Helmholtz-Zentrum Dresden-Rossendorf"], ["V Vishwakarma", 2020, "Publications Repository-Helmholtz-Zentrum Dresden-Rossendorf"], ["Vishal Kukreti", 2019, "The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of \u2026"], ["Manjula Maganti", 2019, "The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of \u2026"], ["Robert Kridel", 2019, "The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of \u2026"], ["Richard Tsang", 2019, "The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of \u2026"], ["David C Hodgson", 2019, "The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of \u2026"], ["Anca Prica", 2019, "The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of \u2026"], ["John Kuruvilla", 2019, "The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of \u2026"], ["Lourdes Calvente", 2019, "The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of \u2026"], ["Michael Crump", 2019, "The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of \u2026"], ["Alexander Sun", 2019, "The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of \u2026"], ["Danielle Rodin", 2019, "The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of \u2026"], ["E Zucca", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["U Vitolo", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["U Ricardi", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["L Nassi", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["G Ciccone", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["F Merli", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["A Lopez-Guillermo", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["MG Cabras", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["A Conconi", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["MK Gospodarowicz", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["M Martelli", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["A Chiappella", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["A Vanazzi", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["M Balzarotti", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["A Tucci", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["AL Molinari", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["M Tani", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["AJM Ferreri", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["H Gomez", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["AH Sarris", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["V Pavone", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["F Cavalli", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["S Storti", 2019, "THE ROLE OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS AND CONTRALATERAL TESTIS RADIOTHERAPY IN PRIMARY TESTICULAR LYMPHOMA: LONG TERM ANALYSIS OF THE PHASE II IELSG10 STUDY AND \u2026"], ["Surbhi Grover", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["May Abdel-Wahab", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Andrew D Trister", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Clifton David Fuller", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Joshua Jones", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["C Norman Coleman", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Patrick Kupelian", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Jeffrey C Buchsbaum", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Silvia C Formenti", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Charles R Thomas", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Kavita V Dharmarajan", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["John Longo", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Neha Vapiwala", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Daniel G Petereit", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Joanne B Weidhaas", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Mei Ling Yap", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Joel Goldwein", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Mary-Helen Barcellos-Hoff", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Ronald D Ennis", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Paul Okunieff", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Margaret A Tucker", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Reid F Thompson", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Timur Mitin", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Alan H Epstein", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Anthony L Zietman", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Lawrence N Shulman", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Bhadrasain Vikram", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["John D Boice", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["James A Hayman", 2019, "Enhancing Career Paths for Tomorrow's Radiation Oncologists"], ["Ur Metser", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["Antonio Finelli", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["D Green", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["Nathan Perlis", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["Rachel Glicksman", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["Rosanna Chan", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["P Chung", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["David A Jaffray", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["John Valliant", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["Nafisha Lalani", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["AJ Bayley", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["Doug Vines", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["Alexandre Zlotta", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["Neil Eric Fleshner", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["Robert James Hamilton", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["J Helou", 2019, "Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer"], ["Wiebke R\u00f6sler", 2019, "Global Consultation on Cancer Staging: promoting consistent understanding and use"], ["Brian O\u2019Sullivan", 2019, "Global Consultation on Cancer Staging: promoting consistent understanding and use"], ["Fabio Y Moraes", 2019, "Global Consultation on Cancer Staging: promoting consistent understanding and use"], ["David Byrd", 2019, "Global Consultation on Cancer Staging: promoting consistent understanding and use"], ["Malcolm Mason", 2019, "Global Consultation on Cancer Staging: promoting consistent understanding and use"], ["Hisao Asamura", 2019, "Global Consultation on Cancer Staging: promoting consistent understanding and use"], ["Shao Hui Huang", 2019, "Global Consultation on Cancer Staging: promoting consistent understanding and use"], ["Anne Lee", 2019, "Global Consultation on Cancer Staging: promoting consistent understanding and use"], ["J Han van Krieken", 2019, "Global Consultation on Cancer Staging: promoting consistent understanding and use"], ["James Brierley", 2019, "Global Consultation on Cancer Staging: promoting consistent understanding and use"], ["Brian Rous", 2019, "Global Consultation on Cancer Staging: promoting consistent understanding and use"], ["Marion Pi\u00f1eros", 2019, "Global Consultation on Cancer Staging: promoting consistent understanding and use"], ["Julie Torode", 2019, "Global Consultation on Cancer Staging: promoting consistent understanding and use"], ["Emily A Burger", 2019, "Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and \u2026"], ["Michael Barton", 2019, "Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and \u2026"], ["Felicia M Knaul", 2019, "Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and \u2026"], ["Rifat Atun", 2019, "Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and \u2026"], ["Eduardo Zubizarreta", 2019, "Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and \u2026"], ["Yolande Lievens", 2019, "Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and \u2026"], ["Timothy P Hanna", 2019, "Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and \u2026"], ["Michael Milosevic", 2019, "Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and \u2026"], ["Anna Mary Nyakabau", 2019, "Global palliative radiotherapy: a framework to improve access in resource-constrained settings"], ["Jean-Marc Bourque", 2019, "Global palliative radiotherapy: a framework to improve access in resource-constrained settings"], ["Tracy A Balboni", 2019, "Global palliative radiotherapy: a framework to improve access in resource-constrained settings"], ["Christian Ntizimira", 2019, "Global palliative radiotherapy: a framework to improve access in resource-constrained settings"], ["Eric L Krakauer", 2019, "Global palliative radiotherapy: a framework to improve access in resource-constrained settings"], ["Shekinah NC Elmore", 2019, "Global palliative radiotherapy: a framework to improve access in resource-constrained settings"], ["Supriya Chopra", 2019, "Global palliative radiotherapy: a framework to improve access in resource-constrained settings"], ["Jeremy Sturgeon", 2019, "Detection of relapse by low-dose computed tomography during surveillance in stage I testicular germ cell tumours"], ["Lynn Anson-Cartwright", 2019, "Detection of relapse by low-dose computed tomography during surveillance in stage I testicular germ cell tumours"], ["Peter Chung", 2019, "Detection of relapse by low-dose computed tomography during surveillance in stage I testicular germ cell tumours"], ["Tony Panzarella", 2019, "Detection of relapse by low-dose computed tomography during surveillance in stage I testicular germ cell tumours"], ["Michael AS Jewett", 2019, "Detection of relapse by low-dose computed tomography during surveillance in stage I testicular germ cell tumours"], ["Malcolm J Moore", 2019, "Detection of relapse by low-dose computed tomography during surveillance in stage I testicular germ cell tumours"], ["Robert Hamilton", 2019, "Detection of relapse by low-dose computed tomography during surveillance in stage I testicular germ cell tumours"], ["Padraig Warde", 2019, "Detection of relapse by low-dose computed tomography during surveillance in stage I testicular germ cell tumours"], ["Martin E O\u2019Malley", 2019, "Detection of relapse by low-dose computed tomography during surveillance in stage I testicular germ cell tumours"], ["Philippe L Bedard", 2019, "Detection of relapse by low-dose computed tomography during surveillance in stage I testicular germ cell tumours"], ["Aaron R Hansen", 2019, "Detection of relapse by low-dose computed tomography during surveillance in stage I testicular germ cell tumours"], ["Rajaraman Swaminathan", 2019, "Essential TNM: a registry tool to reduce gaps in cancer staging information"], ["Eric Chokunonga", 2019, "Essential TNM: a registry tool to reduce gaps in cancer staging information"], ["Helen Farrugia", 2019, "Essential TNM: a registry tool to reduce gaps in cancer staging information"], ["D Maxwell Parkin", 2019, "Essential TNM: a registry tool to reduce gaps in cancer staging information"], ["Kevin Ward", 2019, "Essential TNM: a registry tool to reduce gaps in cancer staging information"], ["Isabelle Soerjomataram", 2019, "Essential TNM: a registry tool to reduce gaps in cancer staging information"], ["Morten Ervik", 2019, "Essential TNM: a registry tool to reduce gaps in cancer staging information"], ["Brian O'Sullivan", 2019, "Essential TNM: a registry tool to reduce gaps in cancer staging information"], ["Freddie Bray", 2019, "Essential TNM: a registry tool to reduce gaps in cancer staging information"], ["Ariana Znaor", 2019, "Essential TNM: a registry tool to reduce gaps in cancer staging information"], ["Huda Masoud", 2018, "Cancer in Canada: Stage at diagnosis"], ["Hannah K Weir", 2018, "Cancer in Canada: Stage at diagnosis"], ["Nadine Badets", 2018, "Cancer in Canada: Stage at diagnosis"], ["Ryan Woods", 2018, "Cancer in Canada: Stage at diagnosis"], ["Shirley Bryan", 2018, "Cancer in Canada: Stage at diagnosis"], ["Gina Lockwood", 2018, "Cancer in Canada: Stage at diagnosis"], ["Leah Smith", 2018, "Cancer in Canada: Stage at diagnosis"], ["NS Salgado", 2018, "Tumor-Targeted Dose Escalation for Localized Prostate Cancer Using MR-Guided HDR Brachytherapy (HDR) or Integrated VMAT (IB-VMAT). Dosimetry and Early Toxicity Analysis."], ["A Berlin", 2018, "Tumor-Targeted Dose Escalation for Localized Prostate Cancer Using MR-Guided HDR Brachytherapy (HDR) or Integrated VMAT (IB-VMAT). Dosimetry and Early Toxicity Analysis."], ["A Rink", 2018, "Tumor-Targeted Dose Escalation for Localized Prostate Cancer Using MR-Guided HDR Brachytherapy (HDR) or Integrated VMAT (IB-VMAT). Dosimetry and Early Toxicity Analysis."], ["CN Catton", 2018, "Tumor-Targeted Dose Escalation for Localized Prostate Cancer Using MR-Guided HDR Brachytherapy (HDR) or Integrated VMAT (IB-VMAT). Dosimetry and Early Toxicity Analysis."], ["J Lee", 2018, "Tumor-Targeted Dose Escalation for Localized Prostate Cancer Using MR-Guided HDR Brachytherapy (HDR) or Integrated VMAT (IB-VMAT). Dosimetry and Early Toxicity Analysis."], ["T Craig", 2018, "Tumor-Targeted Dose Escalation for Localized Prostate Cancer Using MR-Guided HDR Brachytherapy (HDR) or Integrated VMAT (IB-VMAT). Dosimetry and Early Toxicity Analysis."], ["M Gospodarowicz", 2018, "Tumor-Targeted Dose Escalation for Localized Prostate Cancer Using MR-Guided HDR Brachytherapy (HDR) or Integrated VMAT (IB-VMAT). Dosimetry and Early Toxicity Analysis."], ["PR Warde", 2018, "Tumor-Targeted Dose Escalation for Localized Prostate Cancer Using MR-Guided HDR Brachytherapy (HDR) or Integrated VMAT (IB-VMAT). Dosimetry and Early Toxicity Analysis."], ["B Lao", 2018, "Tumor-Targeted Dose Escalation for Localized Prostate Cancer Using MR-Guided HDR Brachytherapy (HDR) or Integrated VMAT (IB-VMAT). Dosimetry and Early Toxicity Analysis."], ["C Menard", 2018, "Tumor-Targeted Dose Escalation for Localized Prostate Cancer Using MR-Guided HDR Brachytherapy (HDR) or Integrated VMAT (IB-VMAT). Dosimetry and Early Toxicity Analysis."], ["A Sun", 2018, "Outcome and Role of Radiation Therapy in Stage I-II Mesenteric Diffuse Large B-Cell Lymphoma"], ["RW Tsang", 2018, "Outcome and Role of Radiation Therapy in Stage I-II Mesenteric Diffuse Large B-Cell Lymphoma"], ["M Jones", 2018, "Outcome and Role of Radiation Therapy in Stage I-II Mesenteric Diffuse Large B-Cell Lymphoma"], ["MX Qu", 2018, "Outcome and Role of Radiation Therapy in Stage I-II Mesenteric Diffuse Large B-Cell Lymphoma"], ["D Hodgson", 2018, "Outcome and Role of Radiation Therapy in Stage I-II Mesenteric Diffuse Large B-Cell Lymphoma"], ["M Crump", 2018, "Outcome and Role of Radiation Therapy in Stage I-II Mesenteric Diffuse Large B-Cell Lymphoma"], ["SH Huang", 2018, "Global Consultation on Cancer Staging: To Promote Consistent Understanding and Use of Cancer Stage Terminology"], ["F Moraes", 2018, "Global Consultation on Cancer Staging: To Promote Consistent Understanding and Use of Cancer Stage Terminology"], ["J Brierley", 2018, "Global Consultation on Cancer Staging: To Promote Consistent Understanding and Use of Cancer Stage Terminology"], ["M Malcolm", 2018, "Global Consultation on Cancer Staging: To Promote Consistent Understanding and Use of Cancer Stage Terminology"], ["B O'Sullivan", 2018, "Global Consultation on Cancer Staging: To Promote Consistent Understanding and Use of Cancer Stage Terminology"], ["S Huang", 2018, "Global Consultation on Cancer Staging (GCCS): An International Survey Evaluating the Understanding and Use of the Cancer Stage Classification Terminology"], ["FY Moraes", 2018, "Global Consultation on Cancer Staging (GCCS): An International Survey Evaluating the Understanding and Use of the Cancer Stage Classification Terminology"], ["K Ward", 2018, "Essential TNM: A Means to Collect Stage Data in Population-Based Registries in Low-and Middle-Income Countries"], ["F Bray", 2018, "Essential TNM: A Means to Collect Stage Data in Population-Based Registries in Low-and Middle-Income Countries"], ["M Parkin", 2018, "Essential TNM: A Means to Collect Stage Data in Population-Based Registries in Low-and Middle-Income Countries"], ["M Pi\u00f1eros", 2018, "Essential TNM: A Means to Collect Stage Data in Population-Based Registries in Low-and Middle-Income Countries"], ["A Znaor", 2018, "Essential TNM: A Means to Collect Stage Data in Population-Based Registries in Low-and Middle-Income Countries"], ["M Ervick", 2018, "Essential TNM: A Means to Collect Stage Data in Population-Based Registries in Low-and Middle-Income Countries"], ["Chunkit Fung", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Donna Pucci", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Annalynn M Williams", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Mohammad Abu Zaid", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Lois B Travis", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["M Eileen Dolan", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Deborah Silber", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Ryan Cook", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["David J Vaughn", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Deepak Sahasrabudhe", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Kelli Norton", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Sarah Lena Panzer", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Shirin Ardeshir-Rouhani-Fard", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Nancy J Cox", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Debbie Baker", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["George Bosl", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Robert D Frisina", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Cindy Casaceli", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Linda Jacobs", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Sophie D Fossa", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Erin Jacobsen", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Howard D Sesso", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Steven E Lipshultz", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Darren R Feldman", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Robert J Hamilton", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Kevin C Oeffinger", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Mary Jacqueline Brames", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Rob Hamilton", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Stephanie Curreri", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Leslie L Robison", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Clair J Beard", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Patrick Monahan", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Lawrence H Einhorn", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["Eileen Johnson", 2018, "Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score"], ["H\u00e9ctor Arreola-Ornelas", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Irene J Higginson", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Lukas Radbruch", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["MR Rajagopal", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["St\u00e9phane Verguet", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Stephen R Connor", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Jorge Jim\u00e9nez", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Dingle Spence", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Pascal J Goldschmidt-Clermont", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Camilla Zimmerman", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Victoria Y Fan", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Kathleen M Foley", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Sania Nishtar", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Judith A Salerno", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Megan E O'Brien", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Bishnu D Paudel", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Quach Thanh Khanh", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Thomas Hughes-Hallett", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Faith N Mwangi-Powell", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["James F Cleary", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Isaias Gerardo Salas-Herrera", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Emily B Wroe", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Jos\u00e9 R Coss\u00edo D\u00edaz", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Paul E Farmer", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Huda Abu-Saad Huijer", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Pedro E Perez-Cruz", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["David Clark", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Agnes Binagwaho", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Karen J Hofman", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Julio Frenk", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["K Srinath Reddy", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Nahid Bhadelia", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Cynthia Goh", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Sne\u017eana M Bo\u0161njak", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["James Andrew Gillespie", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Christian R Ntizimira", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Emmanuel BK Luyirika", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Diederik Lohman", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Octavio G\u00f3mez-Dant\u00e9s", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Dean T Jamison", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Oscar M\u00e9ndez Carniado", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Natalia M Rodriguez", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Maria E Medina Mora", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Maia Elsner", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["George AO Alleyne", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Karl A Lorenz", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Xiaoxiao Jiang Kwete", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Mar\u00eda del Roc\u00edo S\u00e1enz Madrigal", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Rachel Nugent", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Liliana De Lima", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Afsan Bhadelia", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["David J Hunter", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Felicia Marie Knaul", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Silvia Allende", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Liz Gwyther", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Mariana Calderon", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Julia D Downing", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"], ["Mark R Steedman", 2018, "Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report"]]}